Intravenous iron in inflammatory bowel diseases

Current Opinion in Gastroenterology

Volumn 29, Issue 2, 2013, Pages 201-207

  Gomollón, Fernando ^a   Gisbert, Javier P ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Crohn's disease; inflammatory bowel disease; iron; ulcerative colitis

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERROUS GLUCONATE; FERUMOXYTOL; HEMOGLOBIN; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON SACCHARATE; MONOFER; TRANSFERRIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; BLOOD TRANSFUSION; CROHN DISEASE; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; NONHUMAN; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; HUMANS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAVENOUS; IRON;

EID: 84873414259     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835bdc2e     Document Type: Review

References (97)

1. Gray T. The elements: A visual exploration of every known atom in the universe. New York: Black Dog & Leventhal Publishers, Inc. 2009.
2. Ochiai E. Chemicals for life and living. Berlin; Heidelberg: Springer; 2011.
3. Blain S, Qué guiner B, Armand L, et al. Effect of natural iron fertilization on carbon sequestration in the Southern Ocean. Nature 2007; 446:1070-1074.
4. Wolff GA, Billett DSM, Bett BJ, et al. The effects of natural iron fertilisation on deep-sea ecology: The Crozet Plateau, Southern Indian Ocean. Chin WC, editor. PLoS ONE 2011; 6:e20697.
5. Rouault TA. Microbiology. Pathogenic bacteria prefer heme. Science 2004; 305:1577-1578.
6. Noinaj N, Easley NC, Oke M, et al. Structural basis for iron piracy by pathogenic Neisseria. Nature 2012; 483:53-58.
7. Williams RJP. Iron in evolution. FEBS Lett 2012; 586:479-484.
8. Winterbourn CC. Toxicity of iron and hydrogen peroxide: The Fenton reaction. Toxicol Lett 1995; 82-83:969-974.
9. Brewer GJ. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood) 2007; 232: 323-335.
10. Kell DB. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009; 2:2.
11. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 2010; 84:825-889.
12. Rajapurkar MM, Shah SV, Lele SS, et al. Association of catalytic iron with cardiovascular disease. Am J Cardiol 2012; 109:438-442.
13. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007; 17:93-100.
14. Andrews NC. Forging a field: The golden age of iron biology. Blood 2008; 112:219-230.
15. Beard J, Han O. Systemic iron status. Biochim Biophys Acta 2009; 1790:584-588.
16. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012; 61:933-952.
17. Isanaka S, Aboud S, Mugusi F, et al. Iron Status Predicts Treatment Failure and Mortality in Tuberculosis Patients: A prospective cohort study from Dar es Salaam, Tanzania. PLoS ONE 2012; 7:e37350.
18. Gasche C. Anemia in IBD: The overlooked villain. Inflamm Bowel Dis 2000; 6:142-150.
19. Kullnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24:1507-1523.
20. Gisbert JP, Gomolló n F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103:1299-1307.
21. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13:1545-1553.
22. Kaye P, Abdulla K, Wood J, et al. Iron-induced mucosal pathology of the upper gastrointestinal tract: A common finding in patients on oral iron therapy. Histopathology 2008; 53:311-317.
23. Parsi MA, Yerian LM. Iron ulcers. Clin Gastroenterol Hepatol 2009; 7: A22.
24. Aamodt G, Bukholm G, Jahnsen J, et al., the IBSEN Study Group. The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in Southeastern Norway. Am J Epidemiol 2008; 168:1065-1072.
25. Oldenburg B, Koningsberger JC, van Berge Henegouwen GP, et al. Review article: Iron and inflammatory bowel disease. Aliment Pharmacol Ther 2001; 15:429-438.
26. Morena F, Gisbert JP. Anemia y enfermedad inflamatoria intestinal. Rev Esp de Enfermed Digest 2008; 100:285-293.
27. Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica 2010; 95:175-178.
28. Gomollon F, Gisbert JP. Review: Intravenous iron in digestive diseases: A clinical (re)view. Ther Adv Chronic Dis 2010; 1:67-75.
29. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of antitumor necrosis factor treatment. Haematologica 2010; 95:199-205.
30. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7:599-610.
31. Yates JM. Iron deficiency anaemia in general practice: clinical outcomes over three years and factors influencing diagnostic investigations. Postgrad Med J 2004; 80:405-410.
32. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in nonanaemic iron-deficient adolescent girls. Lancet 1996; 348:992-996.
33. Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in infancy and low socioeconomic status: A longitudinal analysis of cognitive test scores to age 19 years. Arch Pediatr Adolesc Med 2006; 160:1108-1113.
34. Verdon F. Iron supplementation for unexplained fatigue in nonanaemic women: double blind randomised placebo controlled trial. BMJ 2003; 326: 1124-1130.
35. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118:3222-3227.
36. Vaucher P, Druais P-L, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: A randomized controlled trial. CMAJ 2012; 184:1247-1254.
37. Hinton PS, Sinclair LM. Iron supplementation maintains ventilatory threshold and improves energetic efficiency in iron-deficient nonanemic athletes. Eur J Clin Nutr 2006; 61:30-39.
38. Peeling P, Dawson B, Goodman C, et al. Athletic induced iron deficiency: new insights into the role of inflammation, cytokines and hormones. Eur J Appl Physiol 2008; 103:381-391.
39. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nature Rev Cardiol 2011; 31:485-493.
40. Cook J. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18:319-332.
41. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: A gastroenterological perspective. Dig Dis Sci 2010; 55:548-559.
42. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol 2011; 4:177-184.
43. Andrews SC. The Ferritin-like superfamily: Evolution of the biological iron storeman from a rubrerythrin-like ancestor. Biochim Biophys Acta 2010; 1800:691-705.
44. Bermejo F, García-Ló pez S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol 2009; 15:4638-4643.
45. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1 (Supplement 1):S4-S8.
46. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48:1066-1076.
47. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010; 7:599-610.
48. Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohn Colitis 2011; 5:295-300.
49. Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: Beyond the established markers. J Crohn Colitis 2011; 5:381-391.
50. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113:5277-5286.
51. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53:1190-1197.
52. Anonymous. The value of iron in anaemia. CMAJ 1925; 15:1155-1156.
53. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy, and safety. Hematology 2011; 2010:338-347.
54. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15:1485-1491.
55. Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: Is oral iron getting a bad rap quest. Am J Gastroenterol 2011; 106:1872-1879.
56. Hallberg L. Bioavailability of dietary iron in man. Annu Rev Nutr 1981; 1:123-147.
57. Khomenko T, Szabo S, Deng X, et al. Role of iron in the pathogenesis of cysteamine-induced duodenal ulceration in rats. Am J Physiol Gastrointest Liver Physiol 2009; 296:G1277-G1286.
58. Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 2011; 60:325-333.
59. Toblli JE, Cao G,Olivieri L, Angerosa M. Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology 2008; 82:127-137.
60. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010; 25:3631-3640.
61. Heming N, Letté ron P, Driss F, et al. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia. Crit Care Med 2012; 40:2141-2148.
62. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther 2011; 20:51-60.
63. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
64. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006; 12:1101-1106.
65. Ross DN. Oral and intravenous iron therapy in the anaemia of rheumatoid arthritis. Ann Rheum Dis 1950; 10: 358-362.
66. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012S; 1823:1434-1443.
67. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10:1002-1007.
68. Hahn PF, Ross JF, Bale WF, Whipple GH. The utilization of iron and the rapidity of hemoglobin formation in anemia due to blood loss. J Exp Med 1940; 71:731-736.
69. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Lowdose iron therapy is effective in octogenarians. Am J Med 2005; 118:1142-1147.
70. Davidson L, Girdwood RH. Refractory iron-deficiency anaemia treated with intravenous iron. BMJ 1948; 1:733.
71. Nissim JA. Toxic reactions after intravenous saccharated iron oxide in man. BMJ 1954; 1:352-356.
72. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15 (Suppl 2):S93-S98.
73. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-382.
74. Wysowski DK, Swartz L, Vicky Borders-Hemphill B, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85:650-654.
75. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83:580-588.
76. Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 2009; 59:176-190.
77. Rottembourg J, Kadri A, Leonard E, et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011; 26:3262-3267.
78. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012; 28:241-243.
79. Notebaert É, Chauny J-M, Albert M, et al. Short-term benefits and risks of intravenous iron: A systematic review and meta-analysis. Transfusion 2007; 47:1905-1918.
80. Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008; 26:1579-1581.
81. Mearin F, Balboa A, Castells A, et al. Anemia ferropé nica y uso de hierro endovenoso en patología digestiva. Gastroenterol Hepatol 2010; 33:605-613.
82. Gomolló n F, Gisbert JP. Intravenous iron in digestive diseases. Transfus Altern Transfus Med 2012; 12:122-129.
83. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96:2382-2387.
84. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40:1058-1065.
85. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT 1) randomized controlled trial. Am J Gastroenterol 2008; 103:1182-1192.
86. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44:838-845.
87. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. J Crohn Colitis 2012; 6:267-275.
88. Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104:1460-1467.
89. Koutroubakis IE, Oustamanolakis P, Karakoidas C, et al. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci 2009; 55:2327-2331.
90. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor: A randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141:846-853; e2.
91. Maniadakis N, Kourlaba G, Goumenos D, et al. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. CEOR 2012; 4:185-192.
92. Koutroubakis IE. Recent advances in the management of distal ulcerative colitis. WJGPT 2010; 1:43.
93. Jahn MR, Andreasen HB, Fu? tterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer1), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 18:1-12.
94. Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther 2012; 6:43-51.
95. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK healthcare system of introduction of iron isomaltoside 1000.
96. Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. TCRM 2011; 7:501-509.
97. Moreno Ló pez R, Sicilia Aladrén B, Gomolló n García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009; 15:4675-4685.